Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

Inclusion Criteria: * Histologically confirmed diagnosis of nasopharyngeal carcinoma (NPC) (either at initial diagnosis or at recurrence). * NPC associated with EBV infection, determined as: * NPC occurred in association with a raised serum titre of IgA to EBV viral capsid antigen (VCA) in a patient living in an area of high incidence of EBV+ undifferentiated NPC, or * The presence of EBV has been confirmed in the tumour by immunohistochemistry for EBV antigens or in situ hybridization for EBV early RNA (EBER), or * NPC with persistent or recurrent disease occurs in the context of an elevated circulating EBV genome level * Patients with persistent, recurrent or metastatic NPC that have residual EBV DNA following completion of conventional therapy (chemotherapy or radiotherapy). * Patients with residual masses at the site(s) of previous disease that are not progressing and for whom no standard therapy is currently appropriate. * Patients with residual or recurrent disease that is low volume, that is causing minimal or no symptoms and for whom no standard therapy is currently appropriate. * Disease must be not amenable to potentially curative radiotherapy or surgery. * Completion of standard therapy for malignancy at least 4 weeks before trial entry. * Written informed consent and the ability of the patient to co-operate with treatment and follow up must be ensured and documented. * Age greater than 18 years. * World Health Organisation (WHO) performance status of 0 or 1 * Life expectancy of at least 4 months. * Female patients of child-bearing potential are eligible, provided they have a negative pregnancy test prior to enrolment and agree to use appropriate medically approved contraception during the study up to six months after the last vaccination. * Male patients must agree to use appropriate medically approved contraception during the study up to six months after the last vaccination. Exclusion Criteria: * Chemotherapy, radiotherapy, or major surgery received within 4 weeks of trial entry. * Known chronic active infection with Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV). * Current active autoimmune disease. * Current active skin diseases requiring therapy (psoriasis, eczema etc). * Ongoing active infection. * History of anaphylaxis or severe allergy to vaccination. * Allergy to eggs or egg products. * Previous myeloablative therapy followed by an autologous or allogeneic haematopoietic stem cell transplant. * Patients who have had a splenectomy or splenic irradiation, or with known splenic dysfunction. * Receiving current immunosuppressive medication, including corticosteroids (inhaled steroids are acceptable). * Pregnant and lactating women. * Ongoing toxic manifestations of previous treatment. Exceptions to this are alopecia or certain Grade 1 toxicities which in the opinion of the Investigator should not exclude the patient. * Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.